Resverlogix (RVX) AI Stock Analysis

• Market Cap: C$33.20M
• Dividend Yield: N/A
• Average Volume (3M): 37.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 316,167,270
• 10 Day Avg. Volume: 62,041
• 30 Day Avg. Volume: 37,183
• PEG Ratio: -7.25
• Price to Book (P/B): -0.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.10 ▲(1.00% Upside)
• Action: N/A Date: 04/13/26
• Date: Action: N/A 04/13/26

The score is primarily constrained by very weak financial performance (no revenue, sustained losses and cash burn, and negative equity with heavy leverage). Technicals provide only a modest offset due to mixed signals and negative momentum indicators, while valuation remains challenged because the company is loss-making and offers no dividend yield.

Positive Factors

Focused epigenetic pipeline

A clear scientific focus on epigenetic mechanisms and BET proteins gives Resverlogix a differentiated research thesis within cardiovascular and metabolic disease. This concentrated R&D strategy supports deeper expertise, clearer go-to-market options, and makes the company a more defined partner candidate for larger biopharma alliances over months.

Negative Factors

No operating revenue

Absence of revenue means all operations rely on financing or one-time events rather than product sales. This structurally increases execution risk, forces ongoing capital raises to fund R&D, and leaves the firm exposed to financing market cycles and dilution over the next 2–6 months absent a partnering or licensing deal.

Resverlogix Business Overview & Revenue Model

Company Description

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor tha...

Read more

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor tha...

How the Company Makes Money

null...

Resverlogix Financial Statement Overview

Breakdown	Dec 2025	Mar 2025	Dec 2022	Mar 2022	Jul 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-437.53K	-476.75K	0.00	0.00	0.00
EBITDA	-4.77M	-4.25M	-11.74M	-14.87M	―
Net Income	-7.90M	-7.63M	-3.61M	-24.77M	―
Balance Sheet
Total Assets	7.93M	7.34M	8.12M	9.98M	10.71K
Cash, Cash Equivalents and Short-Term Investments	107.80K	99.00K	40.00K	6.00K	87.00
Total Debt	72.77M	81.97M	6.49M	7.04M	0.00
Total Liabilities	96.73M	89.08M	67.40M	69.85M	50.60K
Stockholders Equity	-88.80M	-81.73M	-59.28M	-59.87M	-94.90K
Cash Flow
Free Cash Flow	-3.73M	-4.36M	-3.99M	-8.90M	-4.41K
Operating Cash Flow	-3.73M	-3.89M	-3.54M	-8.02M	-4.40K
Investing Cash Flow	-660.36K	-377.00K	-473.00K	-833.00K	-426.00
Financing Cash Flow	4.39M	4.36M	4.06M	8.81M	4.95K

Resverlogix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCT	46 Neutral	C$45.90M	-0.56	-205.87%	―	―	62.01%
MBX	45 Neutral	C$33.95M	-6.85	-8.01%	―	-26.81%	-161.24%
RVX	42 Neutral	C$33.20M	-2.63	7.84%	―	―	―
XRTX	42 Neutral	C$4.16M	-0.98	-111.11%	―	―	-1939.32%

Resverlogix Corporate Events